Name | Number of supported studies | Average coverage | |
---|---|---|---|
fibroblast | 22 studies | 32% ± 16% | |
non-classical monocyte | 21 studies | 46% ± 21% | |
endothelial cell | 18 studies | 27% ± 10% | |
pericyte | 11 studies | 26% ± 11% | |
smooth muscle cell | 10 studies | 34% ± 13% | |
capillary endothelial cell | 9 studies | 23% ± 10% | |
connective tissue cell | 8 studies | 32% ± 11% | |
endothelial cell of lymphatic vessel | 7 studies | 25% ± 8% | |
oligodendrocyte | 7 studies | 36% ± 14% | |
epithelial cell | 6 studies | 34% ± 16% | |
ciliated cell | 6 studies | 25% ± 6% | |
mesothelial cell | 5 studies | 40% ± 15% | |
neuron | 5 studies | 33% ± 15% | |
podocyte | 4 studies | 38% ± 25% | |
myofibroblast cell | 4 studies | 42% ± 19% | |
endothelial cell of artery | 4 studies | 23% ± 2% | |
basal cell | 4 studies | 31% ± 15% | |
type B pancreatic cell | 3 studies | 49% ± 18% | |
glomerular endothelial cell | 3 studies | 24% ± 4% | |
extravillous trophoblast | 3 studies | 96% ± 2% | |
placental villous trophoblast | 3 studies | 89% ± 8% | |
vein endothelial cell | 3 studies | 21% ± 8% | |
retinal pigment epithelial cell | 3 studies | 37% ± 4% | |
enteroendocrine cell | 3 studies | 25% ± 9% | |
secretory cell | 3 studies | 20% ± 3% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
ovary | 100% | 13542.19 | 180 / 180 | 97% | 56.87 | 416 / 430 |
prostate | 95% | 2266.23 | 232 / 245 | 98% | 22.85 | 491 / 502 |
kidney | 100% | 8139.91 | 89 / 89 | 87% | 27.72 | 782 / 901 |
uterus | 100% | 6008.71 | 170 / 170 | 86% | 53.01 | 397 / 459 |
adrenal gland | 99% | 12462.83 | 256 / 258 | 87% | 57.69 | 200 / 230 |
breast | 100% | 6210.24 | 459 / 459 | 81% | 18.95 | 906 / 1118 |
bladder | 100% | 5451.52 | 21 / 21 | 79% | 28.38 | 399 / 504 |
esophagus | 94% | 3811.06 | 1357 / 1445 | 84% | 26.57 | 154 / 183 |
stomach | 98% | 2695.34 | 353 / 359 | 74% | 23.57 | 213 / 286 |
lung | 90% | 2342.00 | 519 / 578 | 82% | 20.37 | 950 / 1155 |
thymus | 80% | 1126.43 | 522 / 653 | 89% | 20.93 | 537 / 605 |
intestine | 92% | 2447.74 | 885 / 966 | 70% | 15.15 | 367 / 527 |
pancreas | 63% | 880.54 | 206 / 328 | 95% | 35.35 | 169 / 178 |
brain | 53% | 1593.78 | 1409 / 2642 | 94% | 31.28 | 664 / 705 |
skin | 64% | 1182.69 | 1162 / 1809 | 75% | 23.07 | 353 / 472 |
eye | 0% | 0 | 0 / 0 | 100% | 81.48 | 80 / 80 |
adipose | 100% | 8061.14 | 1203 / 1204 | 0% | 0 | 0 / 0 |
blood vessel | 92% | 1977.70 | 1224 / 1335 | 0% | 0 | 0 / 0 |
muscle | 91% | 2261.40 | 734 / 803 | 0% | 0 | 0 / 0 |
heart | 91% | 1924.69 | 783 / 861 | 0% | 0 | 0 / 0 |
spleen | 80% | 1271.48 | 193 / 241 | 0% | 0 | 0 / 0 |
tonsil | 0% | 0 | 0 / 0 | 73% | 24.31 | 33 / 45 |
liver | 6% | 54.48 | 13 / 226 | 30% | 9.17 | 122 / 406 |
peripheral blood | 14% | 177.97 | 132 / 929 | 0% | 0 | 0 / 0 |
lymph node | 0% | 0 | 0 / 0 | 10% | 1.63 | 3 / 29 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
ureter | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 1 |
GO_0030511 | Biological process | positive regulation of transforming growth factor beta receptor signaling pathway |
GO_0033673 | Biological process | negative regulation of kinase activity |
GO_0045930 | Biological process | negative regulation of mitotic cell cycle |
GO_0045893 | Biological process | positive regulation of DNA-templated transcription |
GO_0045736 | Biological process | negative regulation of cyclin-dependent protein serine/threonine kinase activity |
GO_0045892 | Biological process | negative regulation of DNA-templated transcription |
GO_0050680 | Biological process | negative regulation of epithelial cell proliferation |
GO_1904030 | Biological process | negative regulation of cyclin-dependent protein kinase activity |
GO_0042326 | Biological process | negative regulation of phosphorylation |
GO_0005737 | Cellular component | cytoplasm |
GO_0005634 | Cellular component | nucleus |
GO_0044877 | Molecular function | protein-containing complex binding |
GO_0004860 | Molecular function | protein kinase inhibitor activity |
GO_0140678 | Molecular function | molecular function inhibitor activity |
GO_0004861 | Molecular function | cyclin-dependent protein serine/threonine kinase inhibitor activity |
GO_0005515 | Molecular function | protein binding |
Gene name | CDKN1C |
Protein name | Cyclin dependent kinase inhibitor 1C Cyclin-dependent kinase inhibitor 1C transcript variant 3 Cyclin-dependent kinase inhibitor 1C (Cyclin-dependent kinase inhibitor p57) (p57Kip2) Cyclin-dependent kinase inhibitor 1C |
Synonyms | KIP2 |
Description | FUNCTION: Potent tight-binding inhibitor of several G1 cyclin/CDK complexes (cyclin E-CDK2, cyclin D2-CDK4, and cyclin A-CDK2) and, to lesser extent, of the mitotic cyclin B-CDC2. Negative regulator of cell proliferation. May play a role in maintenance of the non-proliferative state throughout life. |
Accessions | ENST00000633020.1 ENST00000313407.10 P49918 A0A0G2JPX0 ENST00000380725.2 ENST00000440480.8 [P49918-2] ENST00000616138.2 ENST00000631604.1 A6NK88 B2D1N3 ENST00000414822.8 [P49918-1] A0A2R8YFP9 A0A0G2JH30 ENST00000647251.1 ENST00000430149.3 [P49918-1] |